NCT02095184 2026-04-15
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
University of Maryland, Baltimore
Phase NA Terminated
Clinical Trials
30 trialsNCT00802711 2026-04-13
3-Dimensional Conformal Radiation Therapy or Internal Radiation Therapy After Breast-Conserving Surgery in Treating Women With Stage I or Stage II Breast Cancer
Cancer Trials Ireland
Phase NA Terminated
NCT05180474 2026-04-13
GEN1047 for Solid Tumors - First in Human (FIH) Trial
Genmab
Phase 1/2 Terminated
NCT04931823 2026-04-03
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Phase 1 Terminated
NCT05076266 2026-04-02
COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation
Eastern Cooperative Oncology Group
Terminated
NCT05744375 2026-04-02
TRANSCENDER
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT04791384 2026-03-31
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
Criterium, Inc.
Phase 1/2 Terminated
NCT04877912 2026-03-20
Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening
University of Chicago
Terminated
NCT01780064 2026-03-18
APAPI
Centre Oscar Lambret
Phase NA Terminated
NCT02570100 2026-03-18
RepriM
Centre Oscar Lambret
Phase NA Terminated
NCT04202640 2026-03-18
PRESSODOU
Centre Oscar Lambret
Phase NA Terminated
NCT01613482 2026-03-16
TSARINE
Centre Oscar Lambret
Phase 3 Terminated
NCT01614704 2026-03-13
Impact of Sequential Chemotherapy on Young Patients Breast Cancer Treated Fertility
Centre Oscar Lambret
Terminated
NCT04796324 2026-03-12
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
Allarity Therapeutics
Phase 2 Terminated
NCT06315296 2026-03-03
An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer
Thomas Jefferson University
Phase NA Terminated
NCT03953326 2026-02-27
HeartPhone Cancer Survivors Trial 2019
Penn State University
Phase 1/2 Terminated
NCT06162663 2026-02-27
Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors
Medical University of South Carolina
Phase 4 Terminated
NCT07441330 2026-02-27
Evaluation of Data Obtained From Three Common Imaging Techniques: Positron Emission Tomography (PET-CT), Breast Ultrasound, and Magnetic Resonance Imaging (MRI) After Neoadjuvant Chemotherapy in Patients With Breast Cancer
Ramsay Générale de Santé
Phase NA Terminated
NCT03428581 2026-02-24
Preventing Lymphedema in Axillary Lymph Node Dissection
Mayo Clinic
Phase NA Terminated
NCT03130439 2026-02-20
Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT05269160 2026-02-17
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)
Baylor College of Medicine
Phase 1/2 Terminated
NCT03101748 2026-02-12
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04504331 2026-02-12
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
Stanford University
Phase 1 Terminated
NCT03237572 2026-02-09
Breast-48
University of Virginia
Phase 1 Terminated
NCT04990895 2026-02-05
A Research Study to Collect Patient Reported Outcomes Using Electronic Surveys
AHS Cancer Control Alberta
Phase NA Terminated
NCT04491864 2026-01-26
DWIBS
Baylor Research Institute
Terminated
NCT04570956 2026-01-23
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk
Mayo Clinic
Phase 2 Terminated
NCT03289039 2026-01-22
Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT03765983 2026-01-22
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT05070247 2026-01-22
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Terminated